Terms: = Ovarian cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4
321 results:
1. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
2. [Preparation and characterization of chicken anti-human B7-H4 IgY polyclonal antibody].
Zhang L; Fan Z; Zhang W; Huang H; Wang J; Hei A; Cong Y; Xu J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Mar; 40(3):257-266. PubMed ID: 38512036
[TBL] [Abstract] [Full Text] [Related]
3. Adjuvant ovarian Function Suppression in Premenopausal Hormone Receptor-Positive Breast cancer.
Basmadjian RB; Lupichuk S; Xu Y; Quan ML; Cheung WY; Brenner DR
JAMA Netw Open; 2024 Mar; 7(3):e242082. PubMed ID: 38477918
[TBL] [Abstract] [Full Text] [Related]
4. EZH2-mediated development of therapeutic resistance in cancer.
Kaur P; Shankar E; Gupta S
Cancer Lett; 2024 Apr; 586():216706. PubMed ID: 38331087
[TBL] [Abstract] [Full Text] [Related]
5. Antibody-Drug Conjugates: Advancing from Magic Bullet to Biological Missile.
Veneziani AC; Sneha S; Oza AM
Clin Cancer Res; 2024 Apr; 30(8):1434-1437. PubMed ID: 38306232
[TBL] [Abstract] [Full Text] [Related]
6. Nanoparticle Targeting in Chemo-Resistant ovarian cancer Reveals Dual Axis of Therapeutic Vulnerability Involving Cholesterol Uptake and Cell Redox Balance.
Wang Y; Calvert AE; Cardenas H; Rink JS; Nahotko D; Qiang W; Ndukwe CE; Chen F; Keathley R; Zhang Y; Cheng JX; Thaxton CS; Matei D
Adv Sci (Weinh); 2024 Apr; 11(13):e2305212. PubMed ID: 38263873
[TBL] [Abstract] [Full Text] [Related]
7. Biomarkers of peripheral blood neutrophil extracellular traps in the diagnosis and progression of malignant tumors.
Wang M; Lv X; Wang Y; Li Y; Li H; Shen Z; Zhao L
Cancer Med; 2024 Feb; 13(3):e6935. PubMed ID: 38230764
[TBL] [Abstract] [Full Text] [Related]
8. Proteomic profiling of ovarian clear cell carcinomas identifies prognostic biomarkers for chemotherapy.
Yue L; Gong T; Jiang W; Qian L; Gong W; Sun Y; Cai X; Xu H; Liu F; Wang H; Li S; Zhu Y; Zheng Z; Wu Q; Guo T
Proteomics; 2024 Mar; 24(6):e2300242. PubMed ID: 38171885
[TBL] [Abstract] [Full Text] [Related]
9. Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7.
Heublein S; Pfisterer J; du Bois A; Anglesio M; Aminossadati B; Bhatti I; Sehouli J; Wimberger P; Schochter F; Hilpert F; Hillemanns P; Kalder M; Schroeder W; Mahner S; Burges A; Canzler U; Gropp-Meier M; Jackisch C; Harter P; Kommoss S; Marmé F
Lab Invest; 2024 Apr; 104(4):100321. PubMed ID: 38154497
[TBL] [Abstract] [Full Text] [Related]
10. DNA methylation sites in early adulthood characterised by pubertal timing and development: a twin study.
Sehovic E; Zellers SM; Youssef MK; Heikkinen A; Kaprio J; Ollikainen M
Clin Epigenetics; 2023 Nov; 15(1):181. PubMed ID: 37950287
[TBL] [Abstract] [Full Text] [Related]
11. A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant cancers with B7-H4 Expression.
Gitto SB; Whicker M; Davies G; Kumar S; Kinneer K; Xu H; Lewis A; Mamidi S; Medvedev S; Kim H; Anderton J; Tang EJ; Ferman B; Coats S; Wilkinson RW; Brown E; Powell DJ; Simpkins F
Clin Cancer Res; 2024 Apr; 30(8):1567-1581. PubMed ID: 37882675
[TBL] [Abstract] [Full Text] [Related]
12. SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models.
Gray E; Ulrich M; Epp A; Younan P; Sahetya D; Hensley K; Allred S; Huang LY; Hahn J; Gahnberg K; Treuting PM; Trueblood ES; Gosink JJ; Thurman R; Wo S; Spahr K; Haass EJ; Snead K; Miller D; Padilla M; Smith AJ; Frantz C; Schrum JP; Nazarenko N; Gardai SJ
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793853
[TBL] [Abstract] [Full Text] [Related]
13. Highly proliferative and hypodifferentiated CAR-T cells targeting B7-H3 enhance antitumor activity against ovarian and triple-negative breast cancers.
Zhang X; Guo H; Chen J; Xu C; Wang L; Ke Y; Gao Y; Zhang B; Zhu J
Cancer Lett; 2023 Sep; 572():216355. PubMed ID: 37597651
[TBL] [Abstract] [Full Text] [Related]
14. Platinum(IV)-Gold(I) Agents with Promising Anticancer Activity: Selected Studies in 2D and 3D Triple-Negative Breast cancer Models.
López-Hernández JE; Nayeem N; Cerón-Carrasco JP; Ahad A; Hafeez A; León IE; Contel M
Chemistry; 2023 Oct; 29(59):e202302045. PubMed ID: 37507346
[TBL] [Abstract] [Full Text] [Related]
15. Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinoma.
Bitler BG; Bailey CA; Yamamoto TM; McMellen A; Kim H; Watson ZL
Mol Carcinog; 2023 Nov; 62(11):1717-1730. PubMed ID: 37493106
[TBL] [Abstract] [Full Text] [Related]
16. Design, Synthesis, and Biological Evaluation of New Urushiol Derivatives as Potent Class I Histone Deacetylase Inhibitors.
Zhou H; Qi Z; Liu D; Xue X; Wang C
Chembiochem; 2023 Sep; 24(18):e202300238. PubMed ID: 37366008
[TBL] [Abstract] [Full Text] [Related]
17. Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of cancer.
Toader D; Fessler SP; Collins SD; Conlon PR; Bollu R; Catcott KC; Chin CN; Dirksen A; Du B; Duvall JR; Higgins S; Kozytska MV; Bellovoda K; Faircloth C; Lee D; Li F; Qin L; Routhier C; Shaw P; Stevenson CA; Wang J; Wongthida P; Ter-Ovanesyan E; Ditty E; Bradley SP; Xu L; Yin M; Yurkovetskiy AV; Mosher R; Damelin M; Lowinger TB
Mol Cancer Ther; 2023 Sep; 22(9):999-1012. PubMed ID: 37294948
[TBL] [Abstract] [Full Text] [Related]
18. Novel chromobox 2 inhibitory peptide decreases tumor progression.
Brubaker LW; Backos DS; Nguyen VT; Reigan P; Yamamoto TM; Woodruff ER; Iwanaga R; Wempe MF; Kumar V; Persenaire C; Watson ZL; Bitler BG
Expert Opin Ther Targets; 2023; 27(4-5):361-371. PubMed ID: 37243607
[TBL] [Abstract] [Full Text] [Related]
19. IFNγ induces Bcl3 expression by JAK1/STAT1/p65 signaling, resulting in increased IL-8 expression in ovarian cancer cells.
Gaire B; Padmanabhan S; Zou Y; Uddin MM; Reddy SU; Vancurova I
FEBS Open Bio; 2023 Aug; 13(8):1495-1506. PubMed ID: 37151134
[TBL] [Abstract] [Full Text] [Related]
20. Oncogene-mediated nuclear accumulation of lactate promotes epigenetic alterations to induce cancer cell proliferation.
Bandopadhyay S; Kamal IM; Padmanaban E; Ghosh DD; Chakrabarti S; Roy SS
J Cell Biochem; 2023 Apr; 124(4):495-519. PubMed ID: 36999756
[TBL] [Abstract] [Full Text] [Related]
[Next]
